HPV Testing And Pap Test Market

Global HPV Testing and Pap Test Market Size (2022 to 2027)

The Global HPV Testing and Pap Test Market size is expected to value USD 4.16 billion in 2022 and is expected to grow at a CAGR of 6.5% during the forecast period and be worth USD 5.71 billion by 2027.

The Human Papillomavirus (HPV) test is an analysis to know the presence of human papillomavirus. This HPV leads to cervical cancer or abnormal cervical cells and the development of genital warts. HPV is a virus that transmits sexually, and it is clinically confirmed that HPV is the fundamental cause of cervical cancer. There are two types of cancers which is commonly seen in women: breast cancer and cervical cancer. Cervical cancer is the second prominent cancer in women. For instance, according to World Health Organisation, cervical cancer is the fourth most common cancer among women. The study says that more than 570,000 new cases were registered in 2018, and it is said that 90% of deaths from cervical cancer occur in emerging and under developing countries. The Papanicolaou test is a cervical screening procedure for identifying potentially pre-cancerous and cancerous processes in the cervix.

MARKET DRIVERS:

The growing aging population, rising number of cervical cancer cases, increasing awareness of cervical cancer screening programs, and government initiative and funding drive the growth of the HPV testing market.

The rising number of cervical and vaginal cancer cases is driving the HPV Testing and Pap Test Market. The growing aging population all around the world and the demand for screening programs are boosting the market. The rising awareness of cervical cancer screening programs is propelling the market growth. Moreover, the beneficial policies of the government about cardiac monitoring and the rise in the investment or funding in R&D for the development of advanced technology are fueling the market. Moreover, to carry out awareness campaigns, the government and major companies are funding the universities for developing enhanced technologies to facilitate effective screening to mitigate the incidence of late-stage cervical cancer.

The rising economy in emerging countries is estimated to grow the HPV Testing and Pap Test Market in the coming years. Moreover, to carry out awareness campaigns, the government and private companies are funding the universities for developing enhanced technologies to facilitate effective screening to mitigate the incidence of late-stage cervical cancer, which boosts the market in the future years. The aforementioned attribute is setting growth opportunities for the market.

MARKET RESTRAINTS:

However, changes in regulatory guidelines for cervical cancer screening and HPV vaccination hinder this market's growth. Additionally, the uncertain reimbursement scenario is a major challenge inhibiting the global HPV testing and PAP test market growth. The changes in the survival guidelines for cervical cancer screening are the primary restraint for the market. The HPV vaccination is stopping the market growth. Moreover, the lack of awareness on pre-cancer screening in emerging countries is the most significant barrier to market growth.

Impact of COVID-19 on the global HPV testing and PAP test market:

The COVID has left an adverse impact on every market. Due to the implementation of lockdown across the world in the first half of 2020, all manufacturing companies, industries, and many others were closed. The global economy was declined during the pandemic. The HPV Testing and Pap Test Market are not any different; the market had gone through rough times. The hospitals only treat the essential patients like COVID patients, and non-essential patients got ignored and rescheduled their treatments, due to which the market shares got declined. Moreover, the disturbance in the supply chain system and the shortage of devices due to lockdown had hindered the HPV Testing and Pap Test Market. The situation is estimated to resume the market, the key players in the market helping the market rise after the pandemic.

REPORT COVERAGE:

This research report on the global HPV testing and PAP test market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2027.

HPV Testing and Pap Test Market - By Test Type:

• HPV Testing
• Follow-up HPV Testing
• HPV Primary Testing
• Co-Testing
• PAP Test

Based on the test type, the Pap test category is estimated to command the largest share of the HPV testing market in 2019. HPV testing category is projected to grow at the highest CAGR in the forecast period because of the growing incidences of cervical cancer, raising awareness of HPV screening, and introducing HPV primary tests.

HPV Testing and Pap Test Market - By Application:

• Vaginal Cancer Screening
• Cervical Cancer Screening

Based on the application, the cervical cancer screening application category is estimated to command the largest share of the Pap test market in 2019. This large share is because of the rising incidences of cervical cancer and government initiatives to increase awareness regarding cervical cancer screening benefits.

HPV Testing and Pap Test Market - By End-users:

• Laboratories
• Hospitals
• Physicians
• Offices
• Clinics

Based on end-users, the laboratories' end-user category is likely to command the Pap test market's most significant share in 2019. Moreover, the hospital's end-user category is estimated to grow at the highest CAGR in the future because most of the diagnostic tests are carried out in-house in hospitals using advanced technologies in a relatively shorter period.

HPV Testing and Pap Test Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American HPV Testing and PAP test market had accounted for a significant share in the global market in the regional analysis, which is around 50%. The value of the target market in this region was approximately USD 1.96 billion in 2020. The presence of a high number of cervix cases in the countries like the US and Canada is one of the major factors driving the HPV Testing and Pap Test Market in North America.

The Europe HPV Testing and Pap Test Market was the second-largest in the global market in 2019, which is around 25% and valued at about USD 0.97 million in 2020. The rising aging population and the growing number of cervical cancer cases are some of the reasons that have augmented the growth of the target market in this region. Also, government initiatives and funding towards this testing in this region's various countries are crucial factors driving the Europe HPV Testing and Pap Test Market.

Whereas, Asia-Pacific HPV Testing and Pap Test Market are expected to grow at the highest CAGR during the forecast period. This anticipation is due to the escalating number of cervical cases in APAC. The rising number of hospital construction and growing developments in the early diagnosis of the diseases are the other factors pushing the market's growth in the area. At present, Asia-Pacific HPV Testing and Pap Test Market are valued around USD 0.59 million in 2020, about 15% of the global market.

KEY MARKET PARTICIPANTS:

Some of the notable companies dominating the Global HPV Testing and PAP Test Market profiled in this report are Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., and Arbor Vita Corporation.

RECENT HAPPENINGS IN THIS MARKET:

• In 2021, QIAGEN N.V., a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, has announced the launch of the QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in North America, Europe and other markets globally.
• In 2021, Hologic, Inc., one of the key players of the HPV Testing and Pap Test Market, has acquired Diagenode, a privately held European developer and manufacturer of molecular diagnostic assays, for approximately $159 million (130 million euros).